natgillin/translations-raw huggingface dataset:
65926 Frankfurt am Main, Deutschland
65926 Frankfurt am Main, Nemčija
Sweden sanofi-aventis AB Box 141 42
Švedska sanofi-aventis AB Box 141 42
Greece sanofi-aventis AEBE 348 Syngrou avenueBuilding A
Grčija sanofi-aventis AEBE 348 Syngrou avenueBuilding A
Estonia sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Estonia
Estonija sanofi-aventis Estonia OÜ, Pärnu mnt 139 E/2, 11317 Tallinn, Estonija
Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS, United Kingdom)
Sanofi-aventis One Onslow Street, Guildford, Surrey, GU1 4YS, Velika Britanija)
Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Cyprus
Sanofi-aventis Cyprus Ltd, 14 Charalambou Mouskou street, 2015 - Nicosia, Ciper
Ireland sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Ireland
Irska sanofi-aventis Ireland Ltd., Citywest Business Campus, Dublin 24, Irska
Sanofi-aventis France 1-13 Boulevard Romain Rolland 75014 Paris FRANCE
Sanofi-aventis France 1-13 Boulevard Romain Rolland 75014 Paris Francija
Slovenia sanofi-aventis d.o.o, Dunajska 151, 1000 Ljubljana, Slovenia
Slovenija sanofi-aventis d.o.o, Dunajska 151, 1000 Ljubljana, Slovenija
Sanofi-Avenstis Bulgaria EOOD, Bulgaria, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8
Sanofi-Avenstis Bulgaria EOOD, Bulgarija, 1303 Sofia, 103 Alexander Stamboliiski Blvd, fl.8
Netherlands sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, The Netherlands
Nizozemska sanofi-aventis Netherlands B.V., Kampenringweg 45 DE, 2803 PE Gouda, Nizozemska
Hungary sanofi-aventis Zrt.
Madžarska sanofi-aventis Zrt.
Finland sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Finland
Finska sanofi-aventis Oy Huopalahdentie 24 00350 Helsinki, Finska
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Germany
Sanofi-Aventis Deutschland GmbH Brüningstrasse 50 D-65 926 Frankfurt am Main, Nemčija
SANOFI-AVENTISProdutos
Portugalska SANOFI-AVENTISProdutos
Italy sanofi-aventis S.p.A. Viale Luigi Bodio 37/B 20158 Milan Italy
Viale Luigi Bodio 37/B 20158 Milan Italija
Tavanic 250 250 mg Film-coated tablets
Tavanic 250 250 mg Filmsko obložene tablete
Tavanic 500 500 mg Film-coated tablets
Tavanic 500 500 mg Filmsko obložene tablete
Tavanic 500mg 500 mg Film-coated tablets
Tavanic 500mg 500 mg Filmsko obložene tablete
This summary was last updated in 02-2016.
Povzetek je bil nazadnje posodobljen MM-2016.
What measures are being taken to ensure the safe and effective use of Zurampic?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zurampic?
Patients should drink plenty of fluids throughout the day.
Bolniki morajo čez dan popiti dovolj tekočine.
What is Zurampic and what is it used for?
Kaj je zdravilo Zurampic in za kaj se uporablja?
The full EPAR and risk management plan summary for Zurampic can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Zurampic sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Risks such as kidney damage or heart problems are addressed in the product information.
Tveganja, kot so poškodbe ledvic in težave s srcem, se obravnavajo v informacijah o zdravilu.
It is not intended to provide practical advice on how to use Zurampic.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Zurampic is available as 200-mg tablets.
Zdravilo Zurampic je na voljo v obliki 200-miligramskih tablet.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Zurampic's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Zurampic večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
What benefits of Zurampic have been shown in studies?
Kakšne koristi je zdravilo Zurampic izkazalo v študijah?
This is a summary of the European public assessment report (EPAR) for Zurampic.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zurampic.
A risk management plan has been developed to ensure that Zurampic is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Zurampic je bil pripravljen načrt obvladovanja tveganj.
Other information about Zurampic
Druge informacije o zdravilu Zurampic
What are the risks associated with Zurampic?
Kakšna tveganja so povezana z zdravilom Zurampic?
Zurampic was studied in two main studies involving over 1,200 adults with gout who were previously treated with allopurinol.
Zdravilo Zurampic so proučevali v dveh glavnih študijah, ki sta vključevali več kot 1 200 odraslih s protinom, ki so se predhodno zdravili z alopurinolom.
Why is Zurampic approved?
Zakaj je bilo zdravilo Zurampic odobreno?
Adding Zurampic 200 mg once daily was effective in 55% (222 of 405) patients.
Dodajanje zdravila Zurampic 200 mg enkrat na dan je bilo učinkovito pri 55 % (222 od 405) bolnikov.
Looking just at patients whose blood uric acid level did not fall sufficiently on treatment with febuxostat alone, the level dropped to less than 50 mg/litre in 44% (26 of 59) patients taking Zurampic compared to 24% (12 of 51) patients taking placebo.
Med bolniki, pri katerih se koncentracija sečne kisline v krvi ob zdravljenju samo s febuksostatom ni dovolj znižala, se je njena koncentracija znižala na manj kot 50 mg/liter pri 44 % (26 od 59) bolnikov, ki so prejemali zdravilo Zurampic, v primerjavi s 24 % (12 od 51) bolnikov, ki so prejemali placebo.
A third main study involved 324 adults who had at least one measurable tophus (large deposit of uric acid in or around a joint or under the skin) and with high blood levels of uric acid (over 80 mg/litre without gout medicines or above 60 mg/litre despite treatment with allopurinol or febuxostat).
Tretja glavna študija je vključevala 324 odraslih, ki so imeli vsaj en merljiv tof (velika zaloga sečne kisline v sklepu ali okoli njega ali pod kožo) in visoko koncentracijo sečne kisline (nad 80 mg/liter brez zdravila za protin ali nad 60 mg/liter kljub zdravljenju z alopurinolom ali febuksostatom).
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zurampic, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The company that markets Zurampic will carry out a study on the risk of heart, circulation or kidney disorders in patients treated with Zurampic, particularly in those who have previously suffered from such disorders.
Družba, ki trži zdravilo Zurampic, bo izvedla študijo o tveganjih za nastanek bolezni srca, ožilja ali ledvic pri bolnikih, ki se zdravijo z zdravilom Zurampic, zlasti pri tistih, ki so že imeli te bolezni.
Overall, Zurampic 200 mg once daily was effective in 57% (60 of 106) patients.
Skupno je bilo zdravilo Zurampic 200 mg enkrat na dan učinkovito pri 57 % (60 od 106) bolnikov.
The most common side effects with Zurampic (which may affect up to 1 in 10 people) are flu, headache, heartburn and (gastro-oesophageal reflux disease) stomach acid coming back to the mouth, and blood tests showing increased blood creatinine levels (a marker of kidney function).
Najpogostejši neželeni učinki zdravila Zurampic (ki lahko prizadenejo največ 1 osebo od 10) so gripa, glavobol, zgaga in (gastroezofagealna refluksna bolezen) vračanje želodčne kisline nazaj v usta ter izvidi krvnih preiskav, ki kažejo na zvišano koncentracijo kreatinina v krvi (označevalec delovanja ledvic).
For more information about treatment with Zurampic, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Zurampic preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The most serious adverse reactions were kidney failure, reduced kidney function, and kidney stones, which affected less than 1 patient in 100.
Najresnejši neželeni učinki so bili ledvična odpoved, okvarjeno delovanje ledvic in ledvični kamni, prizadeli pa so manj kot 1 osebo od 100.
Patients must not take Zurampic if they suffer from tumour lysis syndrome (a complication due to the rapid breakdown of cancer cells during cancer treatment) or a rare hereditary disease called LeschNyhan syndrome, both of which raise uric acid levels in the blood.
Bolniki ne smejo jemati zdravila Zurampic, če imajo sindrom lize tumorja (zaplet zaradi hitre razgradnje rakavih celic med zdravljenjem zaradi raka) ali redko dedno bolezen, imenovano Lesch-Nyhanov sindrom; oba sindroma namreč dvigneta koncentracijo sečne kisline v krvi.
It does this by blocking a protein called ‘uric acid transporter-1' (URAT1) in the kidneys.
To doseže tako, da blokira beljakovino, imenovano prenašalec sečne kisline 1 (URAT1), v ledvicah.
These studies compared the effect of adding Zurampic or placebo (a dummy treatment) to patients' allopurinol treatment.
V teh študijah so primerjali učinek dodajanja zdravila Zurampic ali placeba (zdravila brez zdravilne učinkovine) zdravljenju z alopurinolom.
This compared with 47% (51 of 109) patients given placebo.
Ta delež je pri bolnikih, ki so prejemali placebo, znašal 47 % (51 od 109).
Patients were first treated with febuxostat alone for three weeks and then with febuxostat plus either Zurampic or placebo.
Bolnike so najprej tri tedne zdravili samo s febuksostatom, nato pa s febuksostatom v kombinaciji bodisi z zdravilom Zurampic bodisi s placebom.
The recommended dose is 200 mg once daily, taken in the morning at the same time as a xanthine oxidase inhibitor medicine such as allopurinol or febuxostat.
Priporočeni odmerek je 200 mg enkrat na dan, ki ga je treba vzeti zjutraj hkrati z zaviralcem ksantin-oksidaze, kot sta alopurinol ali febuksostat.
This prevents the build-up of uric acid in joints where it can cause pain, swelling and joint damage.
Tako se prepreči kopičenje sečne kisline v sklepih, kjer povzroča bolečino, otekanje in poškodbe.
The patient's kidney function will be monitored regularly during treatment with Zurampic and the doctor will advise the patient to take sufficient fluid during the day and always take Zurampic with either allopurinol or febuxostat, which helps to prevent kidney damage from Zurampic.
Med zdravljenjem z zdravilom Zurampic bo zdravnik spremljal delovanje bolnikovih ledvic in mu svetoval, naj podnevi popije dovolj tekočine in naj vedno vzame zdravilo Zurampic bodisi z alopurinolom bodisi s febuksostatom, kar preprečuje poškodbe ledvic zaradi zdravila Zurampic.
This is because these disorders have occurred during treatment with Zurampic.
Študijo bodo izvedli zato, ker so se te bolezni že pojavile med zdravljenjem z zdravilom Zurampic.
For practical information about using Zurampic, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Zurampic naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
By blocking URAT1, more uric acid is passed out in the urine and less remains in the blood.
Z zaviranjem beljakovine URAT1 se več sečne kisline izloča z urinom in je manj ostaja v krvi.
Patients with very poor kidney function or who have had a kidney transplant must also not take Zurampic.
Tudi bolniki z zelo okvarjenim delovanjem ledvic ali bolniki s presajenimi ledvicami zdravila Zurampic ne smejo jemati.
If treatment with the xanthine oxidase inhibitor is interrupted, then treatment with Zurampic must also be interrupted at the same time.
Če se zdravljenje z zaviralcem ksantin-oksidaze prekine, je treba takrat prekiniti tudi zdravljenje z zdravilom Zurampic.
Over time, visible deposits of uric acid disappeared in increasing number of patients continuing Zurampic and febuxostat treatment, and fewer patients had recurrence of gout attacks.
Sčasoma so pri čedalje večjem številu bolnikov, ki so nadaljevali zdravljenje z zdravilom Zurampic, vidne zaloge sečne kisline izginile, število bolnikov s ponavljajočimi se napadi protina pa je bilo manjše.
How is Zurampic used?
Kako se zdravilo Zurampic uporablja?
Zurampic is used in combination with a xanthine oxidase inhibitor such as allopurinol or febuxostat.
Zdravilo Zurampic se uporablja v kombinaciji z zaviralcem ksantin-oksidaze, kot sta alopurinol ali febuksostat.
Xanthine oxidase inhibitors reduce the production of uric acid in the body.
Zaviralci ksantin-oksidaze zmanjšajo tvorbo sečne kisline v telesu.
For the full list of all side effects reported with Zurampic, see the package leaflet.
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri zdravilu Zurampic, glejte navodilo za uporabo.
The active substance in Zurampic, lesinurad, helps to remove uric acid from the body.
Zdravilna učinkovina zdravila Zurampic, lesinurad, pripomore k odstranjevanju sečne kisline iz telesa.
Their blood level of uric acid was not sufficiently controlled with allopurinol alone and was above 60 mg/litre at the start of the study.
Alopurinol ni v zadostni meri nadzoroval koncentracije sečne kisline v njihovi krvi, ki je bila na začetku študije nad 60 mg/liter.
It is used in combination with a xanthine oxidase inhibitor, another type of gout medicine, when the xanthine oxidase inhibitor on its own is not able to control uric acid levels sufficiently.
Uporablja se v kombinaciji z zaviralcem ksantin-oksidaze, drugo vrsto zdravila proti protinu, kadar sam zaviralec ksantin-oksidaze ne more v zadostni meri nadzorovati koncentracije sečne kisline.
The main measure of effectiveness was the number of patients whose blood level of uric acid dropped below 60 mg/litre after 6 months of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je koncentracija sečne kisline v krvi po 6 mesecih zdravljenja znižala pod 60 mg/liter.
The main measure of effectiveness was the number of patients whose blood level of uric acid dropped below 50 mg/litre after 6 months of treatment.
Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih se je koncentracija sečne kisline v krvi po 6 mesecih zdravljenja znižala pod 50 mg/liter.
The European Commission granted a marketing authorisation valid throughout the European Union for Zurampic on 18 February 2016.
Evropska komisija je dovoljenje za promet z zdravilom Zurampic, veljavno po vsej Evropski uniji, izdala <datum izdaje dovoljenja za promet z zdravilom>.
Zurampic contains the active substance lesinurad.
Zdravilo Zurampic vsebuje zdravilno učinkovino lesinurad.
How does Zurampic work?
Kako zdravilo Zurampic deluje?
Combined with a xanthine oxidase inhibitor, Zurampic reduced blood levels of uric acid in patients with gout whose high uric acid levels were not sufficiently controlled by a xanthine oxidase inhibitor.
Zdravilo Zurampic je skupaj z zaviralcem ksantin-oksidaze znižalo koncentracijo sečne kisline v krvi pri bolnikih s protinom, pri katerih koncentracija sečne kisline z zaviralcem ksantin-oksidaze ni bila dovolj nadzorovana.
Zurampic is a medicine used in adults with gout to reduce high levels of uric acid in the blood.
Zurampic je zdravilo za zniževanje visoke koncentracije sečne kisline v krvi pri odraslih s protinom.
This compared with 26% (104 of 407) in patients who took placebo in addition to allopurinol.
Pri bolnikih, ki so poleg alopurinola prejemali placebo, je bil ta delež 26 % (104 od 407).
Thus, adding Zurampic to treatment with a xanthine oxidase inhibitor lowers uric acid levels further.
Če se zdravljenju z zaviralcem ksantin-oksidaze doda še zdravilo Zurampic, se koncentracija sečne kisline še bolj zmanjša.
URAT1 normally allows some uric acid to return to the blood after the kidneys have filtered it out.
Ko ledvice izločijo sečno kislino iz krvi, beljakovina URAT1 običajno omogoča, da se je nekaj vrne v kri.
2 (2 x 1) vials + 2 (2 x 1) syringes +2 (2 x 1) needles + 2 (2 x 1) vial adapters + 4 (2 x 2) alcohol pads (multipack)
2 (2 x 1) viali + 2 (2 x 1) brizgi +2 (2 x 1) igli + 2 (2 x 1) polnilca za vialo + 4 (2 x 2) alkoholni zloženci (večkratno pakiranje)
1 vial + 1 syringe + 1 needle + 1 vial adapter + 2 alcohol pads
1 viala + 1 brizga + 1 igla + 1 polnilec za vialo + 2 alkoholna zloženca
1 pre-filled syringe + 2 alcohol pads
1 napolnjena injekcijska brizga + 2 alkoholna zloženca
1 pre-filled pen + 2 alcohol pads
1 napolnjen injekcijski peresnik + 2 alkoholna zloženca
Date of latest renewal: 15th July 2016
Datum zadnjega podaljšanja: 15. julij 2016
(see section 4.4).
(navedeno v poglavju 6).
The leaflet was last revised in {MM/YYYY}.
Navodilo je bilo nazadnje revidirano dne {MM/YYYY}
Table 2: Other indication
Preglednica 2: Druge indikacije
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden vzamete to zdravilo.
Date of first authorisation: 30 September 2011
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 30. september 2011
7 OTHER SPECIAL WARNING(S), IF NECESSARY
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
Approximately 90% of 14C-labelled dose is excreted through the kidneys while less than 2% is found in the faeces.
Približno 90 % odmerka, označenega s 14C, se izloči skozi ledvica, medtem ko v fecesu najdemo manj kot 2 % odmerka.
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000) ; not known (cannot be estimated from the available data).
Neželeni učinki so navedeni po organskih sistemih in razvrščeni po pogostnosti (pričakovano število bolnikov, ki bodo doživeli neželen učinek) v naslednje skupine: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Risk Management Plan (RMP) The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Cimetidine reduced the renal clearance of pramipexole by approximately 34%, presumably by inhibition of the cationic secretory transport system of the renal tubules.
Cimetidin je zmanjšal ledvični očistek pramipeksola za približno 34 %, verjetno z inhibicijo kationskega sekretornega transportnega sistema v ledvičnih tubulih.
Lowest maintenance dose
Najmanjši vzdrževalni odmerek Največji vzdrževalni odmerek
Dose adjustment in patients with hepatic failure is probably not necessary, as approx. 90% of absorbed active substance is excreted through the kidneys.
Prilagoditev odmerka pri bolnikih z jetrno odpovedjo verjetno ni potrebna, ker se približno 90 % absorbirane zdravilne učinkovine izloči skozi ledvice.
However, the potential influence of hepatic insufficiency on Pramipexole Accord pharmacokinetics has not been investigated.
Vendar pa potencialnega vpliva jetrne insuficience na farmakokinetiko zdravila Pramipeksol Accord niso raziskovali.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila: http://www.ema.europa.eu
Tell your doctor if you or your family/carer notices that you are developing mania (agitation, feeling elated or over-excited) or delirium (decreased awareness, confusion or loss of reality).
Povejte zdravniku, če ste sami ali vaši družinski člani/negovalec opazili, da se pri vas razvijata manija (agitacija, vznesenost ali prevelika vznemirjenost) ali delirij (zmanjšano zavedanje, zmedenost, izguba občutka za resničnost).
• Psychosis (e.g. comparable with symptoms of schizophrenia).
- Psihoza (na primer podobni simptomi kot pri shizofreniji).
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Pramipeksol Accord neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Nausea and fatigue were more often reported in female patients treated with Pramipexole Accord (20.8% and 10.5%, respectively) compared to males (6.7% and 7.3%, respectively).
O slabosti in utrujenosti so med zdravljenjem z zdravilom Pramipeksol Accord pogosteje poročali pri ženskah (20,8 % in 10,5 %) kot pri moških (6,7 % in 7,3 %).
In a controlled double blind clinical trial of 2 year duration, initial treatment with pramipexole significantly delayed the onset of motor complications, and reduced their occurrence compared to initial treatment with levodopa.
dvojno slepem, 2 leti trajajočem kliničnem preskušanju je začetno zdravljenje s pramipeksolom pomembno odložilo nastop motoričnih zapletov in zmanjšalo njihovo pojavljanje v primerjavi z začetnim zdravljenjem z levodopo.
SPECIAL STORAGE CONDITIONS Store below 30°C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte na temperaturi pod 30 C.
The European Medicines Agency has waived the obligation to submit the results of studies with Pramipexole Accord in all subsets of the paediatric population in Parkinson's Disease (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij z zdravilom Pramipeksol Accord pri Parkinsonovi bolezni za vse skupine pediatrične populacije (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
All the strengths of Pramipexole Accord tablets are available in alu-alu blisters of 10 tablets per strip, in cartons containing 3 or 10 blister strips (30 or 100 tablets).
Vse jakosti Pramipeksol Accord tablet je možno dobiti v aluminijastih pretisnih omotih po 10 tablet na enem traku, v škatlah ki vsebujejo 3 ali 10 pretisne omote (30 ali 100 tablet).
- Strong impulse to gamble excessively despite serious personal or family consequences.
- močna želja po čezmernem hazardiranju ne glede na posledice za vas ali za družino*,
• Do not throw away any medicines via wastewater or household waste.
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
1st week
1. teden
METHOD AND ROUTE(S) OF ADMINISTRATION: Read the package leaflet before use.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo besedilo.
Other indication, most common adverse reactions
Druge indikacije, najpogostnejši neželeni učinki
Inhibitors/competitors of active renal elimination pathway
Zaviralci/snovi, ki tekmujejo za aktivno pot izločanja skozi ledvice
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujte se z zdravnikom ali s farmacevtom, preden boste vzeli katerokoli zdravilo.
The tablet can be divided into two equal doses.
Tablete lahko razdelimo na enaki polovici.
If you suffer from other indication, you may experience the following side effects:
Če imate druge indikacije, so možni naslednji neželeni učinki:
You may experience that symptoms start earlier than usual, be more intense and involve other limbs.
Možno je, da boste simptome bolezni zaznali bolj zgodaj kot običajno, da bodo bolj intezivni in bodo prisotni tudi pri drugih udih.
Parkinson's disease, most common adverse reactions
Parkinsonova bolezen, najpogostnejši neželeni učinki
Store in the original package in order to protect from light.
Shranjujte v originalni ovojnini, za zagotovitev zaščite pred svetlobo.